We showed that WST11-VTP ablation combined with P-selectin-targeted nanoparticle therapy, along with local Enzalutamide and Paclitaxel, reduced tumor burden and improved survival more effectively than WST11-VTP alone in a mouse model of prostate cancer. This evidence concerns the gene SELP and prostate carcinoma.